Table 2.
Health outcomes and costs of an infant routine vaccination program with PCV13 and PCV10 by scope of benefit compared with no vaccination under the base case scenario [direct effect plus indirect effect for IPD (PCV13 only)], by countrya
| Algeria | Tunisia | |||
|---|---|---|---|---|
| PCV13 vs. no vaccination | PCV10 vs. no vaccination | PCV13 vs. no vaccination | PCV10 vs. no vaccination | |
| Morbidity avoided | ||||
| IPD avoided | 7608 | 2804 | 1305 | 557 |
| Pneumonia avoided | 57,800 | 45,320 | 4833 | 4531 |
| AOM avoided | 283,588 | 222,359 | 54,957 | 51,522 |
| Total cases avoided | 348,997 | 270,483 | 61,095 | 56,610 |
| Mortality avoided | ||||
| Deaths | 2177 | 1224 | 308 | 172 |
| QALYs gained | ||||
| QALYs saved, acute disease avoided | 1837 | 1378 | 323 | 290 |
| QALYs saved, sequelae and death avoided | 56,604 | 34,367 | 7443 | 4852 |
| Total QALYs saved | 58,441 | 35,744 | 7766 | 5142 |
| Base case | ||||
| Direct medical cost | − 25.79 Million $ | − 17.66 Million $ | − 2.24 Million $ | − 1.80 Million $ |
| Vaccination program cost | 43.83 Million $ | 43.83 Million $ | 8.82 Million $ | 8.82 Million $ |
| Net cost, direct medical | 18.04 Million $ | 26.16 Million $ | 6.58 Million $ | 7.03 Million $ |
| Cost per QALY | 308/QALY | 731/QALY | 848/QALY | 1366/QALY |
PCV10 10-valent pneumococcal conjugate vaccine, PCV13 13-valent pneumococcal conjugate vaccine, QALY quality adjusted life year, IPD invasive pneumococcal disease, AOM acute otitis media
aAll monetary values are in US dollars